April 2013

"If you build it, they will come," became a catchphrase thanks to the 1989 movie "Field of Dreams." For the founders of The Urology Center of Colorado (TUCC), it was more than just a saying.

An interview with Frank G. Opelka, MD, exploring some of the health policy initiatives that will impact how physicians will be compensated in the future.

Several case studies highlighting the latest strategies and therapeutic agents available for patients with prostate cancer.

We need to begin to migrate toward a system that embraces evidence-based medicine, and begin the development of protocols and the measurement of quality metrics.

Steve Dobbs, the CEO of Urologic Specialists of Oklahoma, Inc, discusses the viability, legality, and successful implementation of an office-based medication-dispensing solution.

A cost analysis found that para-aortic radiotherapy, dogleg radiotherapy, and 1 cycle of carboplatin are cost-effective strategies for the management of stage I testicular seminoma post-orchiectomy compared with surveillance.

Studies that continue to shed light on the optimal use of sipuleucel-T in men with prostate cancer were presented at the 2013 Genitourinary Cancers Symposium.